CN112272555A - 用于治疗增殖性障碍的给药方案 - Google Patents

用于治疗增殖性障碍的给药方案 Download PDF

Info

Publication number
CN112272555A
CN112272555A CN201980037784.6A CN201980037784A CN112272555A CN 112272555 A CN112272555 A CN 112272555A CN 201980037784 A CN201980037784 A CN 201980037784A CN 112272555 A CN112272555 A CN 112272555A
Authority
CN
China
Prior art keywords
curcumin
liposome
curcuminoid
dmpc
dmpg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980037784.6A
Other languages
English (en)
Chinese (zh)
Inventor
P·索迪洛
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Signpath Pharma Inc
Original Assignee
Signpath Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Signpath Pharma Inc filed Critical Signpath Pharma Inc
Publication of CN112272555A publication Critical patent/CN112272555A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
    • A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
    • A61K47/6911—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a liposome
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Dispersion Chemistry (AREA)
  • Dermatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980037784.6A 2018-04-09 2019-03-28 用于治疗增殖性障碍的给药方案 Pending CN112272555A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862655095P 2018-04-09 2018-04-09
US62/655095 2018-04-09
PCT/US2019/024495 WO2019199469A1 (en) 2018-04-09 2019-03-28 Dosing regimens for treatment of proliferative disorders

Publications (1)

Publication Number Publication Date
CN112272555A true CN112272555A (zh) 2021-01-26

Family

ID=68164516

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980037784.6A Pending CN112272555A (zh) 2018-04-09 2019-03-28 用于治疗增殖性障碍的给药方案

Country Status (11)

Country Link
US (2) US11813356B2 (https=)
EP (1) EP3773529B1 (https=)
JP (2) JP7241426B2 (https=)
KR (2) KR20240027843A (https=)
CN (1) CN112272555A (https=)
AU (1) AU2019250832B2 (https=)
CA (1) CA3096591C (https=)
ES (1) ES3061642T3 (https=)
MX (1) MX2020010651A (https=)
TW (1) TWI737974B (https=)
WO (1) WO2019199469A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI737974B (zh) 2018-04-09 2021-09-01 美商標徑製藥公司 用於治療增生性失調的劑量方案
EP4675742A1 (en) 2023-02-28 2026-01-07 Panasonic Intellectual Property Management Co., Ltd. Non-aqueous electrolyte secondary battery

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1973834A (zh) * 2006-12-15 2007-06-06 中国科学院长春应用化学研究所 姜黄素用于制备治疗恶性肿瘤耐药的逆转药物的应用
CN101766619A (zh) * 2008-12-30 2010-07-07 武汉大学 一种治疗恶性肿瘤的药物组合物及应用
US20150164878A1 (en) * 2013-12-18 2015-06-18 Signpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
US20170079934A1 (en) * 2015-09-18 2017-03-23 Signpath Pharma Inc. Treatment for glioblastoma

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7244448B2 (en) * 2000-06-30 2007-07-17 Tekmira Pharmaceuticals Corporation Liposomal antineoplastic drugs and uses thereof
US8563525B2 (en) * 2004-01-12 2013-10-22 Natrogen Therapeutics International, Inc. Methods of treating an inflammatory-related disease
US7968115B2 (en) * 2004-03-05 2011-06-28 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of cancer
US8784881B2 (en) * 2004-03-05 2014-07-22 Board Of Regents, The University Of Texas System Liposomal curcumin for treatment of diseases
PT2146721E (pt) 2007-05-15 2013-07-18 Otsuka Pharma Co Ltd Métodos de utilização de antagonistas da vasopressina com agentes quimioterapeuticos de antraciclina para reduzir a cardiotoxicidade e/ou melhorar a sobrevivência
EP2501372A4 (en) * 2009-11-19 2013-04-10 Signpath Pharma Inc INTRAVENOUS INFUSION OF CURCUMIN AND CALCIUM CHANNEL BLOCKER
US9170257B2 (en) 2012-06-14 2015-10-27 Signpath Pharma Inc. Method and system for measuring the pharmacokinetics of liposomal curcumin and its metabolite tetrahydrocurcumin
DE112013004278T5 (de) * 2012-08-31 2015-05-21 Signpath Pharma Inc. Curcumin-Er, ein liposomales PLGA-Nanocurcumin mit verlängerter oder verzögerter Freisetzung zur Minimierung der QT-Verlängerung für eine Krebstherapie
US20150147385A1 (en) * 2013-11-22 2015-05-28 Signpath Pharma, Inc. Intravenous synthetic curcumin (s-curcumin) for the treatment of proliferative disorders
KR101755245B1 (ko) 2015-08-12 2017-07-07 연세대학교 원주산학협력단 단량체 염을 이용한 폴리이미드 복합체 제조방법
TWI737974B (zh) 2018-04-09 2021-09-01 美商標徑製藥公司 用於治療增生性失調的劑量方案

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1973834A (zh) * 2006-12-15 2007-06-06 中国科学院长春应用化学研究所 姜黄素用于制备治疗恶性肿瘤耐药的逆转药物的应用
CN101766619A (zh) * 2008-12-30 2010-07-07 武汉大学 一种治疗恶性肿瘤的药物组合物及应用
US20150164878A1 (en) * 2013-12-18 2015-06-18 Signpath Pharma Inc. Liposomal mitigation of drug-induced inhibition of the cardiac ikr channel
US20170079934A1 (en) * 2015-09-18 2017-03-23 Signpath Pharma Inc. Treatment for glioblastoma

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
李志国: "姜黄素抗肿瘤作用研究进展", 《中华临床医师杂志(电子版)》 *

Also Published As

Publication number Publication date
ES3061642T3 (en) 2026-04-06
CA3096591C (en) 2023-06-27
JP7241426B2 (ja) 2023-03-17
US20240050372A1 (en) 2024-02-15
AU2019250832B2 (en) 2022-10-27
US11813356B2 (en) 2023-11-14
EP3773529C0 (en) 2025-12-24
EP3773529A1 (en) 2021-02-17
EP3773529B1 (en) 2025-12-24
TWI737974B (zh) 2021-09-01
JP2023030106A (ja) 2023-03-07
KR102637598B1 (ko) 2024-02-16
AU2019250832A1 (en) 2020-10-29
JP2021521130A (ja) 2021-08-26
WO2019199469A1 (en) 2019-10-17
TW201946613A (zh) 2019-12-16
KR20240027843A (ko) 2024-03-04
US12551436B2 (en) 2026-02-17
KR20200141062A (ko) 2020-12-17
US20210161815A1 (en) 2021-06-03
EP3773529A4 (en) 2021-12-22
MX2020010651A (es) 2021-01-15
CA3096591A1 (en) 2019-10-17

Similar Documents

Publication Publication Date Title
JP6861682B2 (ja) コエンザイムＱ１０（ＣｏＱ１０）の静脈内投与用製剤およびその使用方法
JP2024099034A (ja) １’－シアノ置換カルバヌクレオシド類似体の吸入製剤
US20080103213A1 (en) Liposomal curcumin for treatment of neurofibromatosis
JP2019089791A (ja) コエンザイムｑ１０併用療法を用いた癌の処置方法
US12551436B2 (en) Dosing regimens for treatment of proliferative disorders
US12303513B2 (en) Methods and compositions to treat cancer
US20050008664A1 (en) Compositions and methods related to lipid:emodin formulations
CN114652683B (zh) 一种Mdivi-1纳米长循环脂质体及其制备方法和应用
HK40044373A (en) Dosing regimens for treatment of proliferative disorders
WO2013097266A1 (zh) 一种包裹ly294002的药物制剂
HK1130659A (en) Methods of treating influenza viral infections

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 40044373

Country of ref document: HK

RJ01 Rejection of invention patent application after publication
RJ01 Rejection of invention patent application after publication

Application publication date: 20210126